drug_type
RELEVANT_DRUG
intervention_type
Cell therapy
drug_description
Adoptive cell therapy using Vα24+ invariant natural killer T cells that recognize glycolipid antigens via CD1d, rapidly secrete IFN-γ and other cytokines, directly lyse tumor cells, activate NK and dendritic cells, and remodel the immunosuppressive microenvironment to overcome PD‑1 resistance.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Natural Killer T-Cells
drug_category
CULTURED CELLS
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous invariant natural killer T (iNKT; Va24-Ja18) cells expanded ex vivo and reinfused. They recognize glycolipid antigens presented by CD1d via their invariant TCR, rapidly secrete IFN-gamma and other cytokines, directly lyse tumor cells (perforin/granzyme, Fas/FasL), and activate NK and dendritic cells to remodel the immunosuppressive tumor microenvironment, enhancing antitumor immunity and helping overcome PD-1 resistance.
drug_name
iNKT cells (adoptive autologous invariant natural killer T cells)
nct_id_drug_ref
NCT05962450